COLL

Business Context and Reporting Period

Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended June 30, 2025
Business Overview: Collegium is a biopharmaceutical company focused on pain management and ADHD. Its portfolio includes Jornay PM (ADHD), Belbuca, Xtampza ER, Nucynta ER, Nucynta IR, and Symproic. The company's financial results for the period are significantly influenced by the September 2024 acquisition of Ironshore Therapeutics, Inc., which added Jornay PM to its portfolio.

Key Financial Metrics

Note: Debt figures include Term Notes Payable ($585.2 million carrying value) and Convertible Senior Notes ($237.7 million carrying value) as of June 30, 2025.

Material Changes vs. Prior Period

• Revenue Growth: Net product revenues increased by 29.4% ($42.7 million) in Q2 2025 compared to Q2 2024. This was primarily driven by the inclusion of Jornay PM revenue ($32.6 million) following the Ironshore acquisition. Xtampza ER and Nucynta products also saw revenue increases due to lower gross-to-net adjustments (rebates/returns).
• Operating Expenses: Selling, general, and administrative (SG&A) expenses rose significantly to $73.6 million in Q2 2025 from $43.3 million in Q2 2024. The increase is attributed to higher sales and marketing costs for Jornay PM, increased headcount, and acquisition-related expenses.
• Amortization: Intangible asset amortization increased to $55.5 million in Q2 2025 from $34.5 million in Q2 2024, reflecting the amortization of assets acquired from Ironshore.
• Profitability: While revenue grew, Net Income decreased to $12.0 million in Q2 2025 from $19.6 million in Q2 2024. This decline was due to higher operating expenses and interest costs, partially offset by the absence of a $7.2 million loss on debt extinguishment recorded in Q2 2024.

Guidance, Outlook, and Risks

• Share Repurchases: In July 2025, the Board authorized a new $150 million share repurchase program through December 31, 2026. The previous program expired on June 30, 2025, with $65 million remaining unused.
• Regulatory Environment: The company faces ongoing regulatory scrutiny regarding opioid products. In July 2025, the FDA announced new safety labeling requirements for all opioid pain medications. Additionally, the "One Big Beautiful Bill Act" (OBBBA) was enacted in July 2025, and the company is evaluating its impact on the effective tax rate.
• Intellectual Property Litigation: Collegium is engaged in significant patent litigation with Purdue regarding Xtampza ER and Nucynta products, and with Alvogen and Chemo Research regarding Belbuca. Outcomes remain uncertain and could materially impact commercialization.
• Supply Chain: The company relies on third-party manufacturers and sole suppliers for active pharmaceutical ingredients (APIs). Shortages in the ADHD market (methylphenidate) have been noted, though Jornay PM has not yet experienced supply issues.
• Non-GAAP Measures: Management highlights Adjusted EBITDA of $105.1 million for Q2 2025 and $200.2 million for the six-month period, excluding amortization, stock-based compensation, and acquisition-related costs.

Investor Verification Checklist

• Jornay PM Commercialization: Verify the trajectory of Jornay PM sales and the success of the integrated sales force in the ADHD market.
• Rebate and Return Estimates: Review the assumptions behind gross-to-net adjustments, as revenue growth was partially driven by favorable changes in rebate settlements and return estimates.
• Debt Service Capacity: Assess the company's ability to service its ~$858 million debt load, including the variable-rate 2024 Term Loan and the 2029 Convertible Notes, amidst rising interest rates.
• Patent Litigation Status: Monitor the status of pending lawsuits with Purdue, Alvogen, and Chemo Research, as adverse rulings could threaten core product exclusivity.
• Regulatory Compliance: Track the impact of new FDA opioid labeling requirements and the OBBBA tax legislation on future margins and tax provisions.